Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated With Checkpoint Blockade

Cancer immunology research - United States
doi 10.1158/2326-6066.cir-16-0329
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

The Clinical Implications of Soluble PD-L1 in Hepatocellular Carcinoma Patients Treated With Radiation Therapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Endothelial PD-L1 Expression as a Biomarker for Acute Rejection in Heart Transplantation

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models

Oncotarget
Oncology
2019English

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced With Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1

Small
Materials ScienceNanoscienceEngineeringBiomaterialsMedicineBiotechnologyNanotechnologyChemistry
2018English

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison

Clinical Cancer Research
Cancer ResearchOncology
2017English

Beyond PD-1 Immunotherapy in Malignant Melanoma

Dermatology and Therapy
Dermatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy